GHRP-2
Also known as: Growth Hormone Releasing Peptide-2
GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist that stimulates pituitary growth hormone release. It is approved in Japan (Kaken Pharmaceutical, 2004) as a single-dose diagnostic agent for GH deficiency, but is NOT FDA-approved in the US and is research-only. Unlike ipamorelin, GHRP-2 is non-selective and modestly raises ACTH, cortisol, and prolactin.
Pricing for GHRP-2
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for GHRP-2
8 third-party tests across 4 vendors. Each card links to the full report.
For
GHRP-2
by Moglabs· batch GH202
For
GHRP-2
by Simple Peptide· batch GHRP2-100032026-1
For
GHRP-2
by Simple Peptide· batch GHRP2-022026
For
GHRP-2
by Ion Peptide· batch GH2-S-122825
For
GHRP-2
by Moglabs· batch hg2001
For
GHRP-2
by Peptide Tech· batch G2-001
For
GHRP-2
by Ion Peptide· batch GHP25-01272026
Purity not on file
For
GHRP-2
by Certified Peptides· batch GHRP21025
14 citations indexed for GHRP-2
Study · 2026
Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions
Growth hormone-releasing peptides (GHRPs) comprise a group of small synthetic peptides that can effectively influence growth hormone secretion both in humans and animals.
review · 2026
Pituitary dysfunction in trans-sellar encephalocele: a two-case report and a literature review
Trans-sellar encephalocele (TSE) is a rare congenital anomaly of the cranial base characterized by herniation of intracranial contents through the sellar floor. Although clinical presentations are diverse, the prevalence and characteristics of endocrine dysfunction due to hypothalamic-pituitary involvement are unclear.
Study · 2026
Behavioral Therapy Ameliorates Severe Obesity With Low Levels of Plasma GH and IGF-1: A Case Report
We encountered a patient with a body mass index of 50.7 kg/m 2 . Behavioral therapy was effective for preventing progression of health disturbance in this case. When coping with severe obesity, we must promote various tests to differentiate secondary obesity.
Study · 2026
Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone
Long COVID (LC) may involve endocrine dysfunction; however, the underlying mechanism remains unclear.
review · 2026
Thyrotroph Pituitary Neuroendocrine Tumors: Molecular Pathology, Diagnostic Challenges, and Receptor-Targeted Therapeutic Strategies
review · 2026
Systematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport
Introduction The proliferation of dietary supplement use among athletes has heightened concerns over inadvertent doping due to contamination with substances prohibited by the World Anti-Doping Agency (WADA) and other undeclared pharmacological adulterants.